The vaccine, iNCOVACC (BBV154), is now available on CoWin, and priced at Rs 800 for private markets
and Rs 325 for supplies to the Centre and state governments, the Hyderabad-based company said.
Last month, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC.
It is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilised SARS-CoV-2 spike protein.
Bharat Biotech’s Intranasal Covid Vaccine Priced At Rs 325 In Govt Hospitals, Rs 800 In Private
The world’s first intranasal Covid-19 vaccine will be rolled out in the fourth week of January at a price of
Rs 325 in government hospitals and at Rs 800 in private hospitals.
Bharat Biotech’s intranasal Covid vaccine iNCOVACC would be available from the fourth week of January
at a price of Rs 325 in government hospitals and at Rs 800 in private hospitals.
The vaccine will be listed on the CoWin app and has been approved to be rolled out as a booster dose for those above 18 years of age.
INCOVACC was developed in partnership with Washington University, St. Louis, which had designed and
developed the recombinant adenoviral vectored construct and evaluated it in preclinical studies for efficacy.
Product development related to preclinical safety evaluation, large-scale manufacturing scale-up.
formulation and delivery device development, including human clinical trials, were conducted by Bharat Biotech.
Product development and clinical trials were funded in part by the Government of India, through the Department of Biotechnology’s, COVID-19 Suraksha Program.